On November 9, 2015 Foundation Medicine, Inc. (NASDAQ:FMI) reported that the company and its collaborators will present three oral and four poster presentations at the 2015 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting taking place December 5 – 8, 2015 in Orlando, Florida (Press release, Foundation Medicine, NOV 9, 2015, View Source [SID:1234508109]). Collectively, the presentations will focus on the application of FoundationOne Heme to identify druggable genomic alterations, inform personalized treatment strategies and improve clinical outcomes across a broad range of sarcomas and hematologic malignancies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

FoundationOne Heme is a comprehensive genomic profile that analyzes DNA in 405 genes and RNA in 265 genes that are most commonly altered in hematologic malignancies and sarcomas. The assay provides oncologists and pathologists with clinically relevant genomic alterations to guide treatment options for patients based on the genomic profile of their cancer.

The schedule for oral presentations by Foundation Medicine and/or its collaborators is as follows:

Session Date & Time: Saturday, December 5, 2015, from 12:00-1:30 p.m. ET
Presentation Time: 12:45 p.m. ET
Title: Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia
Publication Number: 88
Location: Tangerine 3 (WF3-4), Level 2
Session: 617 – Acute Myeloid Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Omics-based Approaches for the Identification of Novel Genetic Modalities in AML
Presenter: Fiona Brown, Ph.D., research fellow, Memorial Sloan-Kettering Cancer Center
Collaborators: Memorial Sloan-Kettering Cancer Center, Dana-Farber Cancer Institute, Children’s Hospital Boston, Children’s Oncology Group, Fred Hutchinson Cancer Research Center, The University of Texas MD Anderson Cancer Center, The Ohio State University Comprehensive Cancer Center, Harvard Medical School

Session Date & Time: Sunday, December 6, 2015, from 4:30-6:00 p.m. ET
Presentation Time: 5:45 p.m. ET
Title: Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations
Publication Number: 369
Location: W224ABEF
Session: 651 – Myeloma: Biology and Pathophysiology, Excluding Therapy: Novel Technologies to Evaluate Biology and Prognosis
Presenter: Christopher Heuck, M.D., assistant professor of medicine, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Collaborators: Myeloma Institute for Research and Therapy

Session Date & Time: Monday, December 7, 2015 from 7:00-8:30 a.m. ET
Presentation Time: 7:00 a.m. ET
Title: Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Publication Number: 481
Location: W331
Session: 635 – Myeloproliferative Syndromes: Basic Science I
Presenter: Benjamin Durham, M.D., research fellow, Memorial Sloan-Kettering Cancer Center
Collaborators: Memorial Sloan-Kettering Cancer Center

The schedule for poster presentations by Foundation Medicine and/or its collaborators is as follows:

Poster Display: Saturday, December 5, 2015 from 9:00 a.m.-7:30 p.m. ET
Poster Presentation: Saturday, December 5, 2015 from 5:30-7:30 p.m. ET
Title: Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-cell ALL
Publication Number: 1422
Poster Display Location: Hall A2-A3
Poster Presentation Location: Hall A2-A3
Session: 618 – Acute Lymphoblastic Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster I
Presenter: Franck Rapaport, Ph.D., computational research leader, Leukemia Center, Memorial Sloan-Kettering Cancer Center
Collaborators: Memorial Sloan-Kettering Cancer Center, Montefiore Medical Center, Mayo Clinic, University of Pennsylvania, Shaare Zedek Medical Center, Northwestern University Feinberg School of Medicine, Weill Cornell Medical College

Poster Display: Sunday, December 6, 2015 from 9:00 a.m.-8:00 p.m. ET
Poster Presentation: Sunday, December 6, 2015 from 6:00-8:00 p.m. ET
Title: Predictive and Prognostic Significance of Comprehensive Genomic Profiling in Patients with Diffuse Large B-cell Lymphoma
Publication Number: 2651
Poster Display Location: Hall A2-A3
Poster Presentation Location: Hall A2-A3
Session: 622 – Non-Hodgkin Lymphoma: Biology, Excluding Therapy: Poster II
Presenter: Jie He, senior manager, computational biology analysis, Foundation Medicine

Poster Display: Sunday, December 6, 2015 from 9:00 a.m.-8:00 p.m. ET
Poster Presentation: Sunday, December 6, 2015 from 6:00-8:00 p.m. ET
Title: Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay
Publication Number: 2668
Poster Display Location: Hall A2-A3
Poster Presentation Location: Hall A2-A3
Session: 622 – Non-Hodgkin Lymphoma: Biology, Excluding Therapy: Poster III
Presenter: Connie Lee Batlevi, M.D., Ph.D., hematology/oncology fellow, Memorial Sloan-Kettering Cancer Center
Collaborators: Memorial Sloan-Kettering Cancer Center

Poster Display: Monday, December 7, 2015 from 10:00 a.m.-8:00 p.m. ET
Poster Presentation: Monday, December 7, 2015 from 6:00-8:00 p.m. ET
Title: Comprehensive Genomic Profiling (CGP) of Angioimmunoblastic T-cell Lymphoma (AITL) to Prospectively Inform Diagnosis and Clinical Management
Publication Number: 3898
Poster Display Location: Hall A2-A3
Poster Presentation Location: Hall A2-A3
Session: 622 – Non-Hodgkin Lymphoma: Biology, Excluding Therapy: Poster III
Presenter: Tariq Mughal, M.D., vice president, medical affairs, Foundation Medicine
Collaborators: Memorial Sloan-Kettering Cancer Center, Tufts University Medical Center